The "Clinical Biomarkers Market - A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, End User, and Region - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The global clinical biomarkers market was valued at $24.80 billion in 2023 and is expected to reach $53.20 billion by 2033, growing at a CAGR of 7.93% between 2023 and 2033. The report focuses on the manufacturers of different types of tests based on biomarkers, namely prognostic, predictive, and diagnostic biomarkers, as well as services.
The global clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services. Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
As per this research, the global clinical biomarkers market includes manufacturers and service providers offering proprietary biomarkers testing products and services for clinical diagnostics and research purposes. The study considers tests based on various technologies for different underlying applications in oncology and non-oncology diseases to detect biomarkers. However, the report does not cover instruments and software.
The global clinical biomarkers market is expected to witness high growth, attributed to the growing usage of products and services, the increasing key player initiatives, and the rising government initiatives in clinical biomarkers. The continued significant investments by healthcare companies to meet industry demand and the growing adoption of drug discovery and development, disease risk assessment, and others among major end users are the major factors propelling the growth of the global clinical biomarkers market.
Drug discovery encompasses a rapidly evolving range of assays and systems that facilitate cancer biomarkers, cardiac biomarkers, infectious diseases, and others. Infectious diseases also offer prognostic assessments for a wide range of diseases, as well as assistance with treatment selection and monitoring of drug treatment efficacy.
Market Segmentation
Product Segment to Dominate the Clinical Biomarkers Market (by Offering)
Based on product, the global clinical biomarkers market was led by the product segment, with a 76.59% share in 2022. The report focuses on the manufacturers of different types of biomarkers, namely, prognostic, predictive, and diagnostic biomarkers. Acknowledging the future potential for massive growth in demand for biomarker-based assays, several biotechnology and life science companies, such as Illumina, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche Ltd, have invested substantially to aid further developments in clinical biomarkers market.
Cancer Biomarkers to Witness the Highest Growth between 2023 and 2033
Cancer biomarkers are the biomolecules or the processes observed during the presence of the tumor. These biomolecules could be found in blood, serum, or any other body fluid, indicating the presence of any abnormal process. These biomarkers could be in the form of genetic biomarkers, protein biomarkers, and glycoproteins that are used for the diagnosis or prognosis of a tumor. A few of the biomarkers that have been diagnosed for the development of any diagnostic assay are BRCA1/BRCA2 and EGFR for breast cancer, SSC and TPA for lung cancer, and PSA for prostate cancer.
Next-Generation Sequencing (NGS) to Witness the Highest Growth between 2023 and 2033
Based on technology, the clinical biomarkers market was led by next-generation sequencing, with a 31.55% share in 2022. Next-generation sequencing (NGS) has been increasingly used in cancer genomics research over the last decade (from 2010 to the present) as new sequencing technology has been developed and improved. NGS is a modern and alternative technique that allows clinicians to evaluate several genes of malignancy at the same time. Material from a patient's tumor that has been biopsied or surgically excised can be used for next-generation sequencing.
Contract Research Organization (CRO) to Witness the Highest Growth between 2023 and 2033
Contract research organizations (CROs) primarily use biomarker testing services for purposes related to bioanalysis in support of the pharmaceutical and biotechnology industry as well as research and academic institutions. Also, research and academic institutions are outsourcing identification and sequencing projects to CROs in an attempt to cut down on research costs. As a result, CROs form a considerable part of the end users in the clinical biomarkers market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
The product segment players leading the market captured around 76.59% of the market's presence as of 2022. Services, on the other hand, accounted for approximately 23.41% of the market presence in 2022.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 255 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value (USD) in 2023 | $24.8 Billion |
| Forecasted Market Value (USD) by 2033 | $53.2 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
Market Dynamics
Market Drivers
- Growing Demand for Clinical Biomarker Products
- Increase in Industrial Activity in Clinical Biomarker Landscape
- Environment Changes Provoking Swift Care and Diagnosis
Market Challenges
- High Price of Products/Services Limiting Adoption of Clinical Biomarkers in Low-Income Countries
- Complex Regulatory Frameworks Delaying Approval of New Clinical Biomarkers Tests
- Difficulty in Identifying New Biomarkers
Market Opportunities
- Technological Advancement in Biomarker Testing
- Increased Research Funding for Executing Research and Development Exercise
- Discovery of Novel Biomarkers Expanding Precision Medicine Horizons
Industry Insights
- Regulatory Framework
- Regulatory Framework in the U.S.
- FDA Regulations
- Biomarker Qualification: Evidentiary Framework Guidance for Industry and FDA Staff
- Regulatory Framework in the U.S. for Medical Devices
- Legal Requirements and Framework in Europe
- U.K.
- Germany
- Legal Requirements and Framework in Asia-Pacific
- China
- Japan
- Pharmaceuticals and Medical Devices Agency (PMDA)
- Patent Analysis
- Competitive Index (Unmet Needs and Innovations)
- Pain Points of Manufacturers
Market Overview
- COVID-19 Impact on Global Clinical Biomarkers Market
- COVID-19 Impact on Market Size
- Integration of Artificial Intelligence in Biomarker Discovery
- Increasing Biomarkers Usage in Precision Medicine
- Technologies Being Used in Clinical Biomarker Testing
- Clinical Biomarker Discovery Making Early Disease Diagnosis Possible
Competitive Insights
- Corporate Strategies
- Acquisitions
- Synergistic Activities
- Funding and Business Expansions
- Business Strategies
- Service/Product Launches
- Supply Chain Analysis
- Pricing Analysis
- Pricing Analysis (by Product)
- Pricing Analysis (by Testing Service)
- Market Share Analysis (by Product Manufacturer)
- Market Share Analysis (by Service Provider)
Company Profiles
- Abbott Laboratories
- Agilent Technologies, Inc.
- ALCEN
- Arsenal Capital Partners
- Azenta Life Sciences
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- bioMerieux S.A.
- BGI
- Broad Institute
- Charles River Laboratories
- Caris Life Sciences
- CENTOGENE N.V.
- Discovery Life Sciences (DLS)
- Enzo Biochem Inc.
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories
- Novogene Co., Ltd.
- Personalis Inc.
- QIAGEN N.V.
- Quest Diagnostics Incorporated
- Q2 Solutions
- Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/s2iihg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429583804/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
